Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study BioPharma DiveThe therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.Clinical DataImmunology & InflammationRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said. Clinical DataImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphomaNext: Alamar, Hemab, Kailera, and Seaport advance IPOs Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
